KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardlytics (CDLX) Other Non-Current Liabilities (2017 - 2024)

Historic Other Non-Current Liabilities for Cardlytics (CDLX) over the last 6 years, with Q3 2024 value amounting to $17000.0.

  • Cardlytics' Other Non-Current Liabilities changed N/A to $17000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $17000.0, marking a year-over-year change of. This contributed to the annual value of $73000.0 for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q3 2024, Cardlytics' Other Non-Current Liabilities is $17000.0.
  • In the past 5 years, Cardlytics' Other Non-Current Liabilities registered a high of $4.6 million during Q4 2021, and its lowest value of $17000.0 during Q2 2024.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $679000.0 (2020), whereas its average is $1.1 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 57010.31% in 2021, then crashed by 9690.72% in 2022.
  • Quarter analysis of 5 years shows Cardlytics' Other Non-Current Liabilities stood at $679000.0 in 2020, then soared by 570.1% to $4.6 million in 2021, then plummeted by 99.54% to $21000.0 in 2022, then skyrocketed by 247.62% to $73000.0 in 2023, then tumbled by 76.71% to $17000.0 in 2024.
  • Its Other Non-Current Liabilities was $17000.0 in Q3 2024, compared to $17000.0 in Q2 2024 and $1.7 million in Q1 2024.